View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 15, 2018

Ono Pharma and Merus sign licence deal for bispecific antibody

Japanese Ono Pharmaceutical has signed a research and licence agreement with Netherlands-based immuno-oncology company Merus for the development of a new bispecific antibody to treat autoimmune diseases.

Japanese Ono Pharmaceutical has signed a new research and licence agreement with Netherlands-based immuno-oncology company Merus for the development of a new bispecific antibody to treat autoimmune diseases.

This agreement builds on a research and license agreement the two companies signed in April 2014 for the joint development of bispecific antibody drugs to treat patients with autoimmune diseases. Under the new deal, Ono will use Merus’ Biclonics technology platform to generate a bispecific antibody.

Ono will sponsor the research activities carried out by Merus to create a drug candidate that can bind to various targets designed for the treatment of autoimmune diseases.

“We are glad to expand our collaboration and look forward to realising the next generation of high-value treatments in autoimmune disease area.”

The resulting products will be exclusively developed, manufactured and commercialised by Ono, while Merus will be eligible for an undisclosed upfront payment, milestone payments and mid-single digit royalty on net sales.

Ono Pharmaceutical corporate officer and discovery and research executive director Hiromu Habashita said: “We highly value Merus’ proprietary drug discovery technology which effectively generates full-length human bispecific antibody therapeutics.

“We are glad to expand our collaboration and look forward to realising the next generation ohigh-valueue treatments in autoimmune disease area.”

Merus CEO Ton Logtenberg said: “As we continue to advance and expand Merus’ proprietary pipeline of innovative therapeutic candidates in oncology, we are very excited to work with a collaborator such as Ono to leverage our Biclonics technology platform to develop therapeutics for other disease areas with significant unmet medical needs.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU